An Open-Label, Dose-Finding And Proof Of Concept Study For Probody (Tm) Therapeutics (Probody Tx) In Subjects With Metastatic Or Locally Advanced Unresectable Solid Tumors And/Or Lymphomas
A study for patients with advanced or recurrent solid tumors or lymphomas using study drug CX-072
Sponsor: CytomX Therapeutics
Enrolling: Male and Female Patients
IRB Number: AAAR1037
U.S. Govt. ID: NCT03013491
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This is the first study in humans for an investigational drug called CX-072. CX-072 is a Probody therapeutic directed against PD-L1 (programmed cell death ligand 1). Probody therapeutics are created from antibodies.
This study is closed
Investigator
Do You Qualify?
Have you been diagnosed with advanced solid tumors or lymphoma? Yes No
Are you at least 18 years of age? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE